^
    1d
    Acquired MYC rearrangement potentially associated with ibrutinib resistance in mantle cell lymphoma. (PubMed, Virchows Arch)
    In conclusion, our findings suggest that c-Myc overexpression and MYC rearrangement are associated with ibrutinib resistance in MCL. Detecting MYC rearrangement in selected MCL cases could be critical for optimizing treatment strategies and improving patient outcomes.
    Journal • IO biomarker
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6) • CD5 (CD5 Molecule) • MME (Membrane Metalloendopeptidase) • SOX11 (SRY-Box Transcription Factor 11)
    |
    Imbruvica (ibrutinib)
    1d
    Fixed-duration ibrutinib-venetoclax with MRD-guided ibrutinib-obinutuzumab intensification in first-line chronic lymphocytic leukaemia (HOVON 158/NEXT STEP): primary analysis of a multicentre, open-label, phase 2 trial. (PubMed, Lancet Haematol)
    An intensification strategy guided by response and MRD deepened remissions in individuals with residual disease and spared early responders further treatment. This approach merits further study as an alternative to fixed-duration triplet therapy.
    P2 data • Journal
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Venclexta (venetoclax) • Imbruvica (ibrutinib) • Gazyva (obinutuzumab)
    2d
    Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL) (clinicaltrials.gov)
    P1, N=25, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Nov 2025 --> Nov 2026 | Trial primary completion date: Nov 2025 --> Nov 2026
    Trial completion date • Trial primary completion date
    |
    Imbruvica (ibrutinib) • Rituxan (rituximab) • lenalidomide
    3d
    Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma (clinicaltrials.gov)
    P1/2, N=145, Recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    Venclexta (venetoclax) • Imbruvica (ibrutinib) • lenalidomide • Gazyva (obinutuzumab) • prednisone
    5d
    Ibrutinib Inhibits Tumor Progression, Alleviates Pain, and Protects the Tibia in a Bone Metastasis Model of Lung Cancer. (PubMed, Anticancer Res)
    Ibrutinib effectively inhibited the proliferation and migration of lung cancer cells, and in a lung cancer bone metastasis model, this drug inhibited tumor growth, alleviated pain, and protected the tibial bone.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    |
    Imbruvica (ibrutinib)
    8d
    NCI-2018-00315: Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, City of Hope Medical Center | Trial completion date: Nov 2025 --> Nov 2026 | Trial primary completion date: Nov 2025 --> Nov 2026
    Trial completion date • Trial primary completion date
    |
    CCND1 (Cyclin D1) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    Chr t(11;14)
    |
    Imbruvica (ibrutinib) • pevonedistat (MLN4924)
    9d
    S2005: Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib and Rituximab) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma (clinicaltrials.gov)
    P2, N=92, Suspended, National Cancer Institute (NCI) | Recruiting --> Suspended
    Trial suspension
    |
    Venclexta (venetoclax) • Imbruvica (ibrutinib) • Rituxan (rituximab) • Truxima (rituximab-abbs) • Mabtas (rituximab biosimilar)
    9d
    Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy (clinicaltrials.gov)
    P2, N=79, Recruiting, The First Affiliated Hospital with Nanjing Medical University | Initiation date: Jun 2025 --> Dec 2025
    Trial initiation date
    |
    Venclexta (venetoclax) • Imbruvica (ibrutinib) • Brukinsa (zanubrutinib) • Calquence (acalabrutinib) • Inokai (orelabrutinib)
    10d
    Combination of FTO and BTK inhibitors synergistically suppresses the malignancy of breast cancer cells. (PubMed, Int J Biol Sci)
    Through screening with 27 clinically approved targeted therapy drugs, we discovered that ibrutinib, a BTK inhibitor, shows the highest cell death rate and lowest combination index (CI)...Collectively, the combined inhibition of FTO and BTK exhibited substantial synergistic anticancer effects in breast cancer. Our findings advocate for the evaluation of this combination in clinical trials.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • E2F1 (E2F transcription factor 1)
    |
    Imbruvica (ibrutinib)
    11d
    VENETOCLAX AND IBRUTINIB: TWO PARTNERS FOR THE FRONT-LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA. (PubMed, Crit Rev Oncol Hematol)
    The I+V regimen is generally manageable and well-tolerated, with toxicities consistent with those reported for single-agent use. Nonetheless, concerns regarding cardiovascular toxicities have been raised, particularly among older patients.
    Review • Journal
    |
    TP53 (Tumor protein P53) • IGH (Immunoglobulin Heavy Locus)
    |
    IGH mutation
    |
    Venclexta (venetoclax) • Imbruvica (ibrutinib)
    14d
    BTK inhibitor ibrutinib reduces LPS-induced inflammation in C8-B4 microglia. (PubMed, EXCLI J)
    See also the graphical abstract(Fig. 1).
    Journal • IO biomarker
    |
    TNFA (Tumor Necrosis Factor-Alpha) • NOS3 (Nitric oxide synthase 3)
    |
    Imbruvica (ibrutinib)
    14d
    Microsecond simulations to investigate the structural mechanism of super-resistant double mutations in BTK to the covalent inhibitor ibrutinib in multiple leukemia. (PubMed, Sci Rep)
    PCA and FEL results further revealed the dynamic variations caused by these mutations. These findings underline the significant impact of mutations T474M and C481S on the binding free energy, highlighting the importance of these residues in ibrutinib-BTK interactions.
    Journal
    |
    BTK (Bruton Tyrosine Kinase)
    |
    BTK C481S
    |
    Imbruvica (ibrutinib)